POLYMEDIX CMN STK (GREY:PYMXQ)

PolyMedix, Inc., a biotechnology company, focuses on developing small synthetic molecule compounds for the treatment of infectious diseases and acute cardiovascular disorders. The company, using its proprietary computational drug design technology, creates defensin mimetic antibiotic compounds, heparin antagonist compounds, and other drug compounds for human therapeutic use. Its developing products include PMX-60056, a heptagonist compound to reverse the activity of both heparin and low molecular weight heparins, which is under phase IB clinical trial; and PMX-30063, a broad spectrum IV antibiotic that is under phase IB clinical trial. The company was founded in 2002 and is based in Radnor, Pennsylvania.

Last updated February 8, 2012